Abstract
Adherence to colorectal cancer (CRC) screening strategies is imperfect and is ∼40% for annual fecal immunochemical tests (FIT) and ∼70% for triennial multi-target stool DNA (mt-sDNA) tests, based on cross-sectional data. Many microsimulation analyses have not considered differential adherence across screening modalities, which may lead to inaccurate conclusions regarding comparative effectiveness. We used the CRC-AIM microsimulation model to estimate the impact of varying adherence rates on the relative benefits of FIT and mt-sDNA screening.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
